Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.

You may also be interested in...



Japan Clears Nine Drugs For Approval, But Only A New DPP-4 Is First Out The Gate

Despite MHLW's progress in cutting the drug lag, no drugs from a June 29 batch of approvals are first-to-market save for a DPP-4 from Mitsubishi Tanabe, which enters a crowded market.

Sucampo/Takeda’s Amitiza Gains IBS-C Indication

Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.

Sucampo/Takeda’s Amitiza Gains IBS-C Indication

Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel